Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: A pragmatic, randomized trial. Full Text
BMC Psychiatry, 09/06/2011
Clinical Article
Kjelby E et al. – There was no substantial difference in anti–depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.
Methods- Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years
- Participants were assessed repeatedly using Positive and Negative Syndrome Scale – Depression factor (PANSS–D) and the Calgary Depression Scale for Schizophrenia (CDSS)
- 226 patients included
- Significant time–effect showing steady decline in depressive symptoms in all medication groups demonstrated
- No substantial differences among SGAs in reducing PANSS–D score or CDSS sum score
- Separate analyses of groups with CDSS sum scores >6 or below/equal to 6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses
- High correlation between PANSS–D and the CDSS sum score (r=0.77; p<0.01)
